Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2

Status

Completed 12Terminated 8Active not recruiting 5Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × copanlisib × Clear all
NCT05010096 2022-05-27

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Columbia University

Phase 1 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡